In order to optimize the benefits and minimize toxicities from cancer therapies, we need valid predictive and prognostic biomarkers to select patients to receive anti-PD-1 alone or in combination, and to identify patients as candidates for de–escalation or intensification of cancer treatment. This evidence concerns the gene PDCD1 and cancer.